Your SlideShare is downloading. ×
0
Sympatholytics
Sympatholytics
Sympatholytics
Sympatholytics
Sympatholytics
Sympatholytics
Sympatholytics
Sympatholytics
Sympatholytics
Sympatholytics
Sympatholytics
Sympatholytics
Sympatholytics
Sympatholytics
Sympatholytics
Sympatholytics
Sympatholytics
Sympatholytics
Sympatholytics
Sympatholytics
Sympatholytics
Sympatholytics
Sympatholytics
Sympatholytics
Sympatholytics
Sympatholytics
Sympatholytics
Sympatholytics
Sympatholytics
Sympatholytics
Sympatholytics
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Sympatholytics

2,095

Published on

a presentation about sympatholitic drugs and their mode of actions

a presentation about sympatholitic drugs and their mode of actions

Published in: Education, Health & Medicine
0 Comments
6 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
2,095
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
0
Comments
0
Likes
6
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1.  Have the opposite effect of adrenergic agents Also known as◦ adrenergic antagonists or◦ adrenergic Blocking Agents
  • 2. Receptor Location Mechanism followedAlpha 1 Blader, radial muscleof eye, blood vesselsGq cause constrictionAlpha 2 Smooth muscles GirelaxationBeta 1 SA, AV node, heart GsIncrease heart rateBeta 2 Blood vessels , liver,smooth musclesGsrelaxationBeta 3 lipocytes Gs
  • 3. ◦ Synthesis of NE◦ Storage of NE in vesicles◦ Release of NE◦ Binding to receptors◦ Uptake mechanism◦ Function◦ Metabolism◦ Excretion
  • 4. Classified by the type of adrenergic receptorthey block Alpha1 and alpha2 receptors Beta1 and beta2 and beta 3 receptors
  • 5. PhenoxybenzamineBlock alpha 1 and alpha 2 by linking covalentlyNon selective block alpha 1 and alpha 2Block is irreversibly and new receptors are made
  • 6. CVSVasodilatation – arteriolar and venous BPMagnitude dependent on symp. activity at that timeMore in erect that in supine position– postural hypotensionMore marked if hypovolaemia is presentBaroreflex activation– reflex tachycardia– tends to oppose the fall by  HR and CO
  • 7. OTHER EFFECT↓contraction of trigone and sphincterin blood vessels urine flowinsulin secretion from islet cells(2 blockers)MiosisNasal stuffiness adrenergic sweating
  • 8. α1 – blockers : Clinical usesReduce blood pressureHypertensive emergenciesLong term treatmentPhaeochromocytomaVasodilatationPeripheral vascular insufficiencyTo reverse vasoconstrictor excessImprove urine flowBenign prostatic hyperplasia
  • 9. α1 – blockers : Adverse effects•Postural hypotension( less with α1 selective - venodilatation is less)•Reflex tachycardia ( less with α1 selective)•Salt and water retention•Nasal stuffiness•Miosis•Failure of ejaculation
  • 10. Ergot alkaloids (ergotamine):Partial agonist & blocking propertyAlso affect other receptors (eg. 5-HT, )Therapeutic effects (migraine, uterus) notrelated to  blockade.Uses:Migraine (acute attack)Uterotonic – (methylergonovine) in PPH
  • 11. Phenoxybenzamine: 1 > 2 ;Irreversible :Covalent binding with receptorLong duration of action (14 - 48 hrs)Also blocks 5-HT, ACh & H1 receptorsInhibits neuronal & extra-neuronal uptake of NAAbsorbed from GIT, low bioavailability
  • 12. Clinical use:PhaeochromocytomaControl of BPPrior to surgeryAdverse effects:Postural hypotension,Tachycardia,Nasal stuffiness, ejaculationPhenoxybenzamine
  • 13. Phentolamine : 1 = 2 PVR –  blockade + direct (non adrenergic) HR – Reflex + 2 presynaptic on cardiacsymp. terminalsPoorly absorbed orallyClinical use:PhaeochromocytomaLocal vasoconstrictor excessAdverse effects:Cardiac stimulation :- tachycardia, arrhythmia, anginaGIT Stimulation :diarrhoea;  gastric acid secretion
  • 14. Tolazoline:Similar to phentolamineSlightly less potentBetter absorption from GITRapidly excreted in urineLimited clinical application:peripheral vasospastic disease
  • 15. 1 Selective AgentsPrazosin & Terazosin: 1 >>>> 2Effective in management of hypertensionLow affinity for 2Relative absence of tachycardia↓ Triglycerides & LDL, ↑ HDL (favourable)Both are extensively metabolized by liverPrazosin shows high 1st Pass effect (50%)Oral absorption - goodTerazosin :Bioavailability >90%; >18 h actionUses: Hypertension and BPHAdverse effectsFirst dose effectPostural hypotensionSalt & water retention ( long term use)
  • 16. TamsulosinSelective α1 anatgonistHas greater selectivity for α1A subtypeHas greater efficacy for BPHRelatively smaller effects on blood vesselsDoxazosin:Similar to Prazosin but longer t ½ (22 Hr)Alfuzosin : similar to prazosin
  • 17. Clinical Uses Of  Blockers•Pheochromocytoma•Hypertensive emergencies•Chronic hypertension – non selective blockersare not used•Peripheral vascular diaease– spastic (Raynauds), not morphological•Local vasoconstrictor excess– phentolamine useful- local infiltration•Urinary obstruction – BPH– prazosin, terazosin, tamsulosin•CHFα2- selective antagonists do not have anyrecognised clinical use
  • 18.  Block alpha & beta receptor sites(nonselective) direct or indirect acting on the release ofnorepinephrine and epinephrine Use - Cardiac arrthymias (HR), HTN (cardiac output), angina (O2 demand) SE - CHF, bronchospasm, bradycardia,wheezing
  • 19.  Competative agonist Propanolol Acetabutol
  • 20.  Sympatholytic1 adrenergic antagonistClass II antiarrhytmic AntihypertensiveAntianginalBronchoconstrictor Symptoms of overdose include extreme bradycardia, advancedatrioventricular block, intraventricular conductiondefects, hypotension, severe congestive heart failure, seizures, andin susceptible patients, bronchospasm, and hypoglycemia
  • 21.  Sympatholytic1 adrenergic antagonist AntihypertensiveAntiarrhythmicAntianginalBronchoconstrictor Symptoms of an atenolol overdose include a slow heartbeat, shortness ofbreath, fainting, dizziness, weakness, confusion, nausea, and vomiting
  • 22.  Sympatholytic1 adrenergic antagonist AntihypertensiveGlaucoma medicationBronchoconstrictor Predicted symptoms of overdose includebradycardia, congestive heart failure, hypotension,bronchospasm, and hypoglycemia.
  • 23.  Sympatholytic adrenergic antagonist Treatment for heart failure Not expected to be toxic followingingestion.
  • 24.  Sympatholytic adrenergic antagonist Bronchoconstrictor
  • 25.  Sympatholytic1 adrenergic antagonist AntihypertensiveHeart failure medicationBronchoconstrictor
  • 26.  Sympatholytic adrenergic antagonist Antihypertensive Symptoms of overdose include abdominalirritation, central nervous systemdepression, coma, extremely slowheartbeat, heart failure, lethargy, low bloodpressure, and wheezing
  • 27.  Sympatholytic adrenergic antagonist AntihypertensiveBronchoconstrictor Symptoms of overdose includedrowsiness, vertigo, headache, andatriventricular block.
  • 28.  www. wikipedia.com www. cvpharmacology.com www.about-pharmacology.com Goodman & Gilman’s the pharmacologicalbasis of therapeutics 12th edition Modern pharmacology with clinicalapplications by Charles R.Craig, RobertE.Stitzel 5th edition Textbook of medical physiology 11th editionby Guyton & Hall

×